Nanjing Libowei Pharmaceutical Co., Ltd.

It is planned to conduct a randomized, single-blind, dose-escalation, placebo-controlled tolerance, pharmacokinetics and drug interaction study in healthy subjects to evaluate the safety and tolerability of single and multiple doses of YK-1169 in healthy subjects, the pharmacokinetic characteristics of single and multiple doses in healthy subjects, and the drug interaction between cefepime and avibactam.